Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help the National Institute for Health and Care Excellence develop guidance on mild cognitive impairment.

The National Institute for Health and Care Excellence (NICE) develops its guidance independently, on the basis of an assessment of the available evidence.

To support timely decision making regarding the use of disease-modifying dementia treatments (DMDTs) in the National Health Service, and to facilitate the development of useful and useable NICE guidance, the NICE’s Health Technology Assessment Innovation Laboratory identified the key issues that might arise during the evaluation of DMDTs and concluded that the NICE’s current approach and methods are appropriate for evaluating these treatments.

The NICE is currently evaluating two new licensed disease-modifying treatments for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease, and has been unable to recommend them in its draft guidance. However, the NICE has not yet published final guidance and will take the comments received in response to its draft guidance fully into account in developing its final recommendations.

A number of other disease-modifying treatments for dementia are in late-stage development and are expected to come to market in the next few years. To prepare for the new generation of dementia treatments in development, NHS England is working to ensure the diagnostic and treatment capacity, clinical pathway redesign, and investment are in place to support the adoption of any new licensed and NICE recommended treatments as soon as possible.